Drug Profile

Parsatuzumab - Genentech

Alternative Names: Anti-EGFL7 - Genentech; M-444A; M0444A; MEGF-0444A; RG-7414; RO-5490248

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genentech
Developer Chugai Pharmaceutical; Genentech
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action EGFL7 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Colorectal cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

17 Oct 2013 Discontinued - Phase-I for Solid tumours (combination therapy, late-stage disease, second-line therapy or greater) in USA (IV)
17 Oct 2013 Discontinued - Phase-I for Solid tumours (monotherapy) in USA (IV)
17 Oct 2013 Discontinued - Phase-I for Solid tumours in Japan (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com